Literature DB >> 2666238

[Double-blind controlled study of the efficacy of nifuroxazide versus placebo in the treatment of acute diarrhea in adults].

P Bourée1, J C Chaput, F Krainik, H Michel, C Trépo.   

Abstract

In a double-blind, controlled randomized trial, 88 adult patients with acute diarrhea (more than three watery stools per day) received either 400 mg of nifuroxazide twice daily or placebo for 5 days. The mean duration of diarrhea in the nifuroxazide group was 2.09 days versus 3.26 days in the placebo group (p less than 0.004). The number of bowel movements per day diminished and mucus disappeared more quickly in patients treated by nifuroxazide than in patients of the placebo group. Nifuroxazide was well tolerated and no side effects were observed. Nifuroxazide is an effective therapy for acute diarrhea and can be prescribed from the onset of diarrhea without waiting for stool culture results which can be late or negative.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2666238

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  7 in total

Review 1.  Diarrhoea in adults (acute).

Authors:  Thomas Gottlieb; Christopher Stewart Heather
Journal:  BMJ Clin Evid       Date:  2011-02-15

2.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors:  Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

Review 3.  Diarrhoea in adults (acute).

Authors:  Guy de Bruyn
Journal:  BMJ Clin Evid       Date:  2008-03-04

4.  Open Clinical Trial on Using Nifuroxazide Compared to Probiotics in Treating Acute Diarrhoeas in Adults.

Authors:  Begler Begovic; Sead Ahmedtagic; Lejla Calkic; Midhat Vehabović; Sanela Bakić Kovacevic; Tarik Catic; Meliha Mehic
Journal:  Mater Sociomed       Date:  2016-12

5.  Nifuroxazide ameliorates lipid and glucose metabolism in palmitate-induced HepG2 cells.

Authors:  Jing-Yi Liu; Yi-Chen Zhang; Li-Ni Song; Lin Zhang; Fang-Yuan Yang; Xiao-Rong Zhu; Zhi-Qiang Cheng; Xi Cao; Jin-Kui Yang
Journal:  RSC Adv       Date:  2019-11-29       Impact factor: 3.361

6.  NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.

Authors:  Haluk Yuzugullu; Thanh Von; Lauren M Thorpe; Sarah R Walker; Thomas M Roberts; David A Frank; Jean J Zhao
Journal:  Cell Discov       Date:  2016-09-20       Impact factor: 10.849

7.  ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells.

Authors:  Sana Sarvi; Richard Crispin; Yuting Lu; Lifan Zeng; Thomas D Hurley; Douglas R Houston; Alex von Kriegsheim; Che-Hong Chen; Daria Mochly-Rosen; Marco Ranzani; Marie E Mathers; Xiaowei Xu; Wei Xu; David J Adams; Neil O Carragher; Mayumi Fujita; Lynn Schuchter; Asier Unciti-Broceta; Valerie G Brunton; E Elizabeth Patton
Journal:  Cell Chem Biol       Date:  2018-10-04       Impact factor: 8.116

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.